Search Results - "Brohl, A.S."

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma by Pollack, M.H., Betof, A., Dearden, H., Rapazzo, K., Valentine, I., Brohl, A.S., Ancell, K.K., Long, G.V., Menzies, A.M., Eroglu, Z., Johnson, D.B., Shoushtari, A.N.

“…Combined cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) blockade induces high rates of immune-related adverse events (irAEs). The…”
Get full text

1667O - Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS) by Jones, R.L., Ravi, V., Brohl, A.S., Chawla, S.P., Ganjoo, K., Italiano, A., Attia, S., Burgess, M., Thornton, K., Cranmer, L., Liu, L., Theuer, C., Maki, R.

“…Pazopanib (P) is approved for refractory advanced STS refractory. A retrospective study of 40 AS patients treated with P, reported a median progression-free…”
Get full text

Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS) by Jones, R.L., Ravi, V., Brohl, A.S., Chawla, S.P., Ganjoo, K., Italiano, A., Attia, S., Burgess, M., Thornton, K., Cranmer, L., Liu, L., Theuer, C., Maki, R.

Get full text

1092P Non-progression with avelumab treatment in patients with metastatic Merkel cell carcinoma (mMCC) is associated with a clinically meaningful better health-related quality of life compared with progressive disease by Bharmal, M., Nolte, S., Lebbé, C., Mortier, L., Brohl, A.S., Fazio, N., Grob, J-J., Prinzi, N., Hanna, G.J., Hassel, J., Kiecker, F., Ellers-Lenz, B., Bajars, M., Guezel, G., Nghiem, P., Hunger, M., Schlichting, M., Henry-Szatkowski, M., D'Angelo, S.

Get full text

A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report by Kim, S., Khushalani, N.I., Eroglu, Z., Russell, J., Wuthrick, E., Caudell, J., Harrison, L., Aoki, M., Shah, H., Blakaj, D., Markowitz, J., Chen, D.-T., Messina, J., Rose, T., Tsai, K., Brohl, A.S.

Get full text

1321P - A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report by Kim, S., Khushalani, N.I., Eroglu, Z., Russell, J., Wuthrick, E., Caudell, J., Harrison, L., Aoki, M., Shah, H., Blakaj, D., Markowitz, J., Chen, D.-T., Messina, J., Rose, T., Tsai, K., Brohl, A.S.

“…MCC is an aggressive cutaneous malignancy. Though checkpoint inhibitor therapy has dramatically improved the treatment landscape, outcome remains poor for…”
Get full text

PCN8 COMPARING PATIENT-RELEVANT ENDPOINT WITH CLINICAL ENDPOINT IN A RARE DISEASE: THE CASE OF METASTATIC MERKEL CELL CARCINOMA TREATED WITH AVELUMAB by Bharmal, M., Nolte, S., Lebbe, C., Mortier, L., Brohl, A.S., Fazio, N., Grob, J.J., Pusceddu, S., Hanna, G.J., Hassel, J.C., Kiecker, F., Ellers-Lenz, B., Bajars, M., Güzel, G., Nghiem, P., Hunger, M., Schlichting, M., Henry-Szatkowski, M., D'Angelo, S.P.

Get full text

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up by D'Angelo, S.P., Bhatia, S., Brohl, A.S., Hamid, O., Mehnert, J.M., Terheyden, P., Shih, K.C., Brownell, I., Lebbé, C., Lewis, K.D., Linette, G.P., Milella, M., Xiong, H., Guezel, G., Nghiem, P.T.

“…Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer that has a poor prognosis in patients with advanced disease. Avelumab [anti-programmed…”
Get full text

First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study by D’Angelo, S.P., Lebbé, C., Mortier, L., Brohl, A.S., Fazio, N., Grob, J.-J., Prinzi, N., Hanna, G.J., Hassel, J.C., Kiecker, F., von Heydebreck, A., Güzel, G., Nghiem, P.

“…Results from the JAVELIN Merkel 200 study led to the approval of avelumab [an anti–programmed death-ligand 1 (PD-L1) antibody] for the treatment of metastatic…”
Get full text